Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Now Covered by Analysts at Royal Bank Of Canada

Stock analysts at Royal Bank Of Canada started coverage on shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) in a report released on Friday. The firm set an “outperform” rating and a $40.00 price target on the stock. Royal Bank Of Canada’s price target points to a potential upside of 57.36% from the company’s current price.

DMRA has been the subject of several other reports. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price for the company. Guggenheim restated a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research report on Friday, January 9th. UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price on the stock. Finally, Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA opened at $25.42 on Friday. The company has a fifty day moving average of $27.13 and a 200 day moving average of $22.61. Damora Therapeutics, Inc. Common Stock has a fifty-two week low of $2.45 and a fifty-two week high of $38.33. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -2.10 and a beta of 1.59.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Ikarian Capital LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $6,574,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $2,774,000. Remedium Capital Partners LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $2,772,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $2,204,000. Finally, Connective Capital Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the third quarter valued at about $100,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.